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a  b  s  t  r  a  c  t
Increasing  numbers  of long-term  cancer  survivors  face important  treatment  related  adverse  effects.  Can-
cer  treatment  induced  metabolic  syndrome  (CTIMetS)  is  an  especially  prevalent  and  harmful  condition.
The  aetiology  of  CTIMetS  likely  differs  from  metabolic  syndrome  in the  general  population,  but  effec-
tive  treatment  and prevention  methods  are  probably  similar.  In this  review,  we  summarize  the  potential







more,  we  propose  a safe  and  accessible  method  to  treat or  prevent  CTIMetS  through  lifestyle  change.  In
particular,  we suggest  that  a lifestyle  intervention  and optimization  of  energy  balance  can  prevent  or
mitigate  the  development  of  CTIMetS,  which  may  contribute  to  optimal  survivorship  care.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY
∗ Corresponding author at: Department of Medical Oncology, University of
roningen, University Medical Centre Groningen, PO Box 30001, 9700, RB Gronin-
en, The Netherlands.
E-mail address: a.walenkamp@umcg.nl (A.M.E. Walenkamp).
ttp://dx.doi.org/10.1016/j.critrevonc.2016.10.011
040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
1. IntroductionThe number of long-term cancer survivors is growing. Accord-
ing to recent data, the age-adjusted 5-year survival in Europe was
about 50% for all cancer types (Baili et al., 2015). Factors like bet-
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Criteria of the metabolic syndrome according to the NCEP ATP III.
Three or more of the following:
Male Female





Blood pressure (mmHg)* systolic ≥ 130/diastolic ≥ 85


















































(Or drug treatment for respectively low HDL, elevated triglycerides, elevated blood
ressure or elevated plasma glucose.
er cancer-care organization (e.g. screening, prevention programs,
ccess to medical facilities), more effective treatment options,
vidence based tumour-speciﬁc protocols and a more multidis-
iplinary approach have contributed to this (Baili et al., 2015;
award, 2006 Haward, 2006). The encouraging increase in overall
urvival is accompanied by increasing numbers of cancer survivors
hose prognosis and quality of life are hampered by the potentially
armful long-term and late side effects of their treatments. Long-
erm survivors of childhood, breast, colorectal and testicular cancer
nd of several haematological malignancies face an increased risk of
reatment-induced cardiovascular disease (Lenihan and Cardinale,
012) and metabolic syndrome (MetS) (de Haas et al., 2010). MetS is
 clustering of central obesity, insulin resistance, dyslipidaemia and
ypertension (de Haas et al., 2010, 2013). This syndrome is associ-
ted with inﬂammatory and prothrombotic features and might be
n important link between cancer treatment, cardiovascular toxic-
ty and accelerated atherosclerosis in cancer survivors (Van Gaal
t al., 2006). The high prevalence of weight gain and sedentary
ifestyle in this population (Irwin, 2009; Kroenke et al., 2005), is
 contributing factor to the higher occurrence of MetS and cardio-
ascular morbidity in cancer survivors. Besides the fact that obesity
s rapidly taking over smoking as the most preventable cause of can-
er in the United States (Arnold et al., 2015; US Cancer Statistics,
012), it is plausible that obesity is part of a vicious circle of cancer
reatment-related fatigue (Minton et al., 2013), impaired physical
unction, discomfort, physical inactivity and continued weight gain
Lucia et al., 2003). One of the possible ways to safely and effectively
reat MetS in the general population is a lifestyle intervention with
he goal to optimize energy balance by increasing physical activ-
ty and reducing caloric intake. Although the aetiology of MetS in
on-cancer patients probably differs from the aetiology in cancer
atients (de Haas et al., 2010), it is reasonable to assume that the
ame treatment strategies may  have similar positive effects on the
revention and treatment of the different components of MetS.
In this review, we focus on the aetiology of the different com-
onents of CTIMetS and corresponding measures to prevent or
itigate this syndrome. We  summarize different types of cancer
nd cancer treatments and their relation to CTIMetS. Furthermore,
e review if interventions regarding exercise level or diet can inﬂu-
nce CTIMetS. Finally, we discuss the inﬂuence of timing of these
nterventions.
. The metabolic syndrome
According to Grundy (2008), at least 25% of the population in
he Americas, Europe and India has MetS. The commonly used
riteria for MetS are those deﬁned by the National Cholesterol Edu-
ation Program’s Adult Treatment Panel (NCEP ATP) III (Evaluation
nd Treatment of High Blood Cholesterol in Adult, 2001; Grundy
t al., 2005) (Table 1). Patients with MetS are at increased risk
f developing a cardiovascular event or type 2 diabetes mellitus
Sattar et al., 2008; Eckel et al., 2010). Early detection of insulinlogy/Hematology 108 (2016) 128–136 129
resistance, dyslipidaemia and/or hypertension or their aetiologi-
cal factors makes treatment or prevention possible with the aim
to reduce cardiovascular morbidity (Eckel et al., 2010). Obesity
can be considered as a major driving force in the development of
MetS, leading to both cardiometabolic risk and insulin resistance
(Giugliano et al., 2008; Kahn, 2007) and is the ﬁrst component that
should be dealt with (Fig. 1). A key aspect of this process is thought
to be the release of free fatty acids (FFAs) (Boden, 2008). Adipose
tissue stores and releases adipokines and FFAs, which have been
linked to insulin-resistance (Boden et al., 1994). More adipose tis-
sue mass releases more FFAs. Moreover, the antilipolytic action of
insulin is inhibited by elevated levels of plasma FFAs, which further
increases FFA release (Jensen et al., 1989). Obesity and insulin resis-
tance are associated with increased production of very low density
lipoprotein triglycerides by the liver. The increase in FFAs and
hyperinsulinaemia are believed to be responsible for this (Bamba
and Rader, 2007). Insulin resistance reduces endothelial produc-
tion of nitric oxide, which results in decreased vasodilatation and
increased blood pressure, with hypertension occurring more fre-
quently (Boden, 2008).
3. Cancer treatment induced metabolic syndrome
The aetiology of CTIMetS is multifactorial and differs between
treatment type, cancer diagnosis and patients characteristics.
Surgery, radiotherapy, chemotherapy and hormonal therapy have
been shown to induce MetS, probably due to different and some-
times overlapping mechanisms (Table 2). In Table 3, an overview of
the odds ratios or relative risk of MetS in different patient groups
is given.
3.1. The role of surgery
Pituitary or hypothalamic damage can result in hormonal dis-
turbances, for example after surgical treatment for brain tumours
(Pietila et al., 2009). Pietilä et al. reported that 8% of brain tumour
patients, mean age 14.4 years, had MetS, and this was associ-
ated with pituitary or hypothalamic damage (P = 0.003). Additional
cranial radiotherapy made these patients even more prone to hor-
monal disturbances and, as a consequence, to CTIMetS in 20% of the
patients (Pietila et al., 2009).
Orchiectomy in testicular cancer survivors may result in gonadal
endocrine dysfunction, i.e. low testosterone and/or high luteinizing
hormone (LH) levels (primary hypogonadism). After the removal of
one testicle, LH may  increase, which is probably the result of fewer
Leydig cells. The remaining Leydig cells have to be more active to
produce sufﬁcient amounts of testosterone. Low testosterone levels
are related to CTIMetS (Nuver et al., 2005).
Risk-reducing salpingo-oophorectomy (RRSO) is also strongly
associated with CTIMetS. Michelsen et al. (2009) found an associa-
tion with CTIMetS with an odds ratio (OR) of 2.46 (95% conﬁdence
interval (CI) 1.63–3.73) in women who had undergone RRSO (mean
follow-up 6.5 years) (Table 3) compared to the general population.
Especially waist circumference and central obesity were determi-
native criteria in the scoring of CTIMetS. Probably, loss of oestrogen
causes alterations in body fat distribution with increased waist cir-
cumference and central obesity (Michelsen et al., 2009). Careful
follow-up for these women  is clearly advisable.
3.2. The role of radiotherapy
Cranial radiotherapy in particular is strongly associated with
disturbances in the hypothalamus-pituitary axis, which has mostly
been studied in childhood cancer survivors. For example, deﬁciency
of growth hormone is the most common endocrine dysfunction in
patients treated with cranial radiotherapy and is associated with









Fig. 1. Physical activity is a safe and effective way of coping with cancer treatment induced metabolic syndrome (CTIMetS) or possibly preventing it. Obesity is frequently
the  major driving force behind the metabolic syndrome and CTIMetS and is the main target for lifestyle intervention.
Table 2
Overview of different types of cancer treatment with possible mechanisms of cancer treatment induced metabolic syndrome (CTIMetS).
Treatment Speciﬁed treatment Mechanism Associated with
Surgery Brain surgery with damage to
pituitary and hypothalamus.








Radiotherapy Cranial radiotherapy Hormonal disturbance: deﬁciency of




Radiation thyroid gland region Hypothyroidism: lower basal
metabolism
Obesity
Total body, chest or abdomen Multiple mechanisms with damage to
one or more organs
Hypertension, dyslipidaemia,
insulin resistance
Chemotherapy Cisplatin Possibly damage to vascular
endothelium, possibly through damage
to mitochondria and production of ROS





Possibly through damage to
mitochondria and production of ROS
Insulin resistance
Antimetabolites Impaired lipid transport Insulin resistance
In  breast cancer patients Sarcopenic obesity CTIMetS, in particular weight
gain
Hormonal therapy Androgen-deprivation therapy Hypogonadism CTIMetS, in particular
dyslipidaemia and insulin
resistance
Anti-estrogenic therapy Hormonal disturbance, possibly by
inhibition of aromatase and less





















besity, dyslipidaemia and insulin resistance (Janiszewski et al.,
007). Growth hormone contributes to lipolysis and has an insulin-
ike inﬂuence. For example, it stimulates production of insulin-like
rowth factor-1, with glucose uptake as a result (de Haas et al.,
010).
Hypothyroidism is seen in patients after radiation to the thy-
oid gland region (e.g. patients with head and neck cancer or
odgkin’s disease). Bölling et al. reported that 24% of patients
median follow-up of 40 months) who received radiotherapy to the
hyroid gland and/or pituitary showed elevated subclinical thyroid-
timulating hormone (TSH) values (Bölling et al., 2011). In onlytion and damage to the
inal ﬂora with reduced dietary
e and insulin secretion
Insulin resistance
37% of these patients, TSH values normalized without intervention
during follow-up. Hypothyroidism, and even low-normal thyroid
hormone levels, can cause a lower basal metabolism and induce
weight gain, which can lead to CTIMetS (Roos et al., 2007).
In a large cohort of 8599 childhood cancer survivors (52% male)
and 2936 siblings (46% male), 5096 patients (59.3%) were treated
with cranial, abdominal, chest, total body, combination or other
radiotherapy. Meacham et al. (2010) showed that exposure to
radiotherapy was associated with three or more of the following
outcomes: body mass index (BMI) ≥ 30 kg/m2, use of medication
for hypertension, dyslipidaemia and impaired glucose metabolism
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Table  3
Increased risk of cancer treatment-induced metabolic syndrome described in several studies in different patient groups with odds ratios or relative risk compared to controls.
Patient group Author, journal and
year of publication
Number of patients Control group Metabolic
syndrome OR or RR




















(2006) J Clin Oncol
20 18 non-ADT and 20
healthy, all
age-matched

























12 CT and 9 SCTb 60 siblings, friends
or neighbours with
same sex and age
range of 5 yr
related to survivor























784 777 age, sex and
race-matched
controls






(2009) Eur J Cancer
326 679 age adjusted,
general population
with no removal of
uterus/ovaries






(2013) Br J Cancer
251 360 healthy,
age-adjusted

















dose > 850 mg
For this table, articles published in English were selected with the search terms [metabolic syndrome x] AND [survivors] AND [neoplasms (or speciﬁc, for example ‘breast
neoplasms’]. For prostate cancer, [survivors] was not used, because this patient group mainly involves patients who are still under treatment. Other selection criteria were:
a  clear odds ratio or relative risk was given or could be extracted from the data, a control group was  used, no intervention was observed and the MetS was deﬁned according
to  the NCEP ATP III criteria.
OR: odds ratio; CI: conﬁdence interval; SD: standard deviation; NS: not speciﬁed; ADT: androgen deprivation therapy; CT: chemotherapy; SCT: Stem cell transplantation;
RR:  relative risk.
a A surrogate endpoint for MetS was used: Cardiovascular Risk Factor Cluster.






















cc In a meta-analysis of 7 studies, 3 studies used NCEP ATPIII criteria. The combine
d OR which was  calculated in patients with a cumulative cisplatin dose of>850 m
e the follow-up time of the group cisplatin >850 mg  was used.
Table 3). In the complete cohort, childhood cancer survivors were
ore likely than siblings to take medications for hypertension (OR
.9, 95% CI 1.6–2.2), dyslipidaemia (OR 1.6, 95% CI 1.3–2.0) or dia-
etes (OR 1.7, 95% CI 1.2–2.3). A combination of direct vascular
oxicity, damage to multiple endocrine organs, like the hypotha-
amus, the pituitary, the thyroid gland or the gonads is probably
esponsible (Meacham et al., 2010).
.3. The role of chemotherapy
Chemotherapy appears to contribute to the pathophysiology
f CTIMetS partially through gonadal toxicity. Chemotherapy may
nduce decreased levels of estrogens and testosterone, which are
ssociated with central obesity, dyslipidaemia and insulin resis-
ance (Carr, 2003; Laaksonen et al., 2004). Alkylating agents, such
s cyclophosphamide and heavy metals, like platinum, are known
o induce gonadal function impairment (de Haas et al., 2010). In
esticular cancer survivors, treatment with chemotherapy is asso-
iated with an increased risk of developing CTIMetS. Weight gain
n testicular cancer survivors is most common in patients who
ave received chemotherapy. Patients who were treated with cis-
latin > 850 mg  had a signiﬁcantly higher mean 10-year BMI  change
ompared to patients who were treated with surgery only. Patientsbers and OR of these 3 studies was  given, calculated by Li et al.
pared to controls.
treated with radiotherapy or lower dose cisplatin (≤850 mg) had no
signiﬁcant 10-year BMI  change compared to surgery. This suggests
that chemotherapeutic treatment with high dosage of cisplatin is
related to weight gain (Table 3) (Sagstuen et al., 2005). In a study
in 173 testicular cancer survivors versus 1085 controls from the
background population with a median follow-up of 5 years, de
Haas et al. (2013) reported that CTIMetS developed at a younger
age in testicular cancer survivors treated with chemotherapy. It
was also found that at a median follow-up of 5 years (range 3–20)
and attained age of 37 years (range 19–59), 44% of the patients
had a low high density lipoprotein cholesterol (‘good’ cholesterol)
(HDL-C) with an OR of 1.7 (95% CI 1.2–2.3) and 29% had high triglyc-
erides with an OR of 1.2 (95% CI 0.8–1.7) in comparison to healthy
age-adjusted controls. In this study, patients with low testosterone
levels (<15 nmol/l) appeared to have an increased risk of CTIMetS
(OR 4.1, 95% CI 1.8–9.3) (de Haas et al., 2013).
The postmenopausal transition in healthy women comes with
declines in lean body mass and increases in fat mass due to nat-
ural ageing, especially in the ﬁrst postmenopausal years (Wang
et al., 1994). Menopause may  develop earlier than expected in
cancer survivors due to chemotherapeutic treatment. It can be dif-
ﬁcult to determine whether changes in adipose tissue and lean
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rated and deleterious process induced by the cancer treatment,
alled sarcopenic obesity (Rock and Demark-Wahnefried, 2002).
evertheless, it is clear that many women treated for breast cancer
ain weight, sometimes with serious consequences like CTIMetS
nd cardiovascular disease (American society of clinical oncology
besity and cancer toolkit, 2014). In the systematic review of Vance
t al., women who had received chemotherapeutic treatment were
ost at risk for gaining weight. Weight gains of 2.5–6.2 kg were
ost commonly reported (Vance et al., 2011). Irwin et al. also
bserved greater weight gain in postmenopausal breast cancer
atients receiving chemotherapy compared to patients receiving
urgery or surgery plus radiotherapy (Irwin et al., 2005). This was
lso observed by Goodwin et al. (1999) who reported that onset
f menopause and chemotherapy independently predict weight
ain. However, it is still unclear whether breast cancer survivors
ain more weight over time compared to the background popula-
ion, also taking into account the potential development of early
enopause and increased obesity in the general population.
Insulin resistance, hyperinsulinaemia or elevated glucose lev-
ls are important aspects of MetS and can also be induced by
hemotherapeutic cancer treatment. A direct inﬂuence of var-
ous chemotherapeutic agents on insulin sensitivity is thought
o be responsible for this. For alkylators, anthracyclines, camp-
othecins (e.g. irinotecan), epipodophyllotoxins (e.g. etoposide) and
latinum-based treatments this could be due to mitochondrial dys-
unction through increased production of reactive oxygen species
ROS) (Rosen et al., 2013). Antimetabolites such as capecitabine can
ecrease hepatic lipid export, causing steatosis, which is associated
ith decreased insulin sensitivity (Floyd et al., 2006). In addition, a
oncomitant cytotoxic treatment adverse event like anaemia may
ause adipose tissue hypoxia, leading to macrophage activation and
nﬂammatory cytokine release (Rosen et al., 2013). These exam-
les show that chemotherapy contributes to the development of
TIMetS mostly through weight gain, but may  also indirectly affect
ther MetS components like dyslipidaemia or insulin resistance.
.4. The role of hormonal therapy
The hormone-modifying treatment with androgen-deprivation
herapy (ADT) in prostate cancer survivors is associated with com-
onents of MetS. Several studies have revealed that drug-induced
ypogonadism causes dyslipidaemia in prostate cancer patients
Saylor and Smith, 2009; Shahani et al., 2008). Shahani et al.
eported a few studies which all showed elevation of triglycerides
nd low density lipoprotein cholesterol (LDL-C). However, HDL-C
lso increased in some studies, which makes it difﬁcult to quan-
ify the cardiovascular risk in this group of patients (Shahani et al.,
008). Keating et al. described an adjusted hazard ratio of 1.44 in
ncident diabetes in men  who were treated with a gonadotropin-
eleasing hormone agonist (Keating et al., 2006). Furthermore, in
atients with pre-existing diabetes, glycaemic control worsened:
9.5% had an increase of HbA1c ≥ 10% and 28.6% had an increase
f fasting blood glucose levels ≥ 10% (Derweesh et al., 2007). In
ow-risk prostate cancer, the risk of cardiovascular disease may  out-
eigh the potential beneﬁt of ADT, negatively inﬂuencing overall
urvival in these patients (Saigal et al., 2007).
Anti-estrogenic therapy is commonly used to treat estrogen-
eceptor positive breast cancer. Because MetS can be a risk factor for
he development of cardiovascular disease, the effects of aromatase
nhibitors and tamoxifen on lipid levels and other cardiovascu-
ar risk factors, are noteworthy. Regarding cardiac adverse events,
romatase inhibitors appear to have a slightly more unfavourable
roﬁle than tamoxifen (absolute difference of 0.52%; RR 1.31, 95%
I 1.07–1.60; P = 0.007), but tamoxifen may  increase the risk of
hrombo-embolism (RR 0.53 95% CI 0.42–0.65, P < 0.0001 in favour
f aromatase inhibitors) (Cuppone et al., 2008). Concerning lipidlogy/Hematology 108 (2016) 128–136
proﬁle, tamoxifen appears to signiﬁcantly decrease total choles-
terol and LDL-C levels in comparison to the aromatase inhibiting
drugs anastrozole and exemestane. Triglycerides tend to increase
slightly with tamoxifen, and HDL-C only differs between the two
aromatase inhibiting drugs (Hozumi et al., 2011). Animal studies
have shown that aromatase is highly present in the cardiovascular
system, especially in the endothelial and smooth muscle system,
which could explain the apparently unfavourable cardiovascular
effect of aromatase inhibiting drugs. Aromatase inhibition leads to
inhibition of estrogen synthesis, resulting in lower nitric oxide pro-
duction, which impairs the protective effect of nitric oxide against
ischemia (Jazbutyte et al., 2012).
3.5. Other cancer treatment-induced mechanisms
Physical inactivity and poor health often coexist during cancer
treatment and may  also be responsible for atrophy and less mus-
cle tissue, which in turn induces a decrease in insulin-stimulated
glucose uptake (Rosen et al., 2013). Damage to the gastrointestinal
tract and liver may  also impair insulin sensitivity. Gut motility is
impaired not only by drugs such as vinca alkaloids, but also by dis-
ruption of the intestinal ﬂora by dietary restrictions and antibiotics,
which are also commonly used during chemotherapy. This results
in a reduction of dietary uptake and inﬂuences the balance of motil-
ity and insulin secretion(Samuel et al., 2008; Stringer et al., 2009).
Notably, inactivity, obesity and diabetes are also risk factors for
the development of various types of cancer. Therefore, at baseline,
cancer patients may  already have a higher chance of developing or
having the MetS (Mendonc¸ a Fernando Miguel, 2015).
4. Intervention options for the metabolic syndrome
4.1. Non-cancer population
In the non-cancer population, achieving a healthy lifestyle by
increasing physical activity in combination with dietary mea-
sures and smoking cessation has been shown to improve the
individual components of MetS and should be the ﬁrst step in
treatment (Grundy et al., 2005). The mainstay in the treatment
of MetS is achieving an optimized energy balance, i.e. a proper
balance between caloric intake and expenditure. More and more
data are available on beneﬁcial effects of lifestyle interventions
to treat MetS and to prevent cardiovascular disease. Yamaoka and
Tango (2012) included eight randomized clinical trials with com-
bined diet and exercise or dietary education alone interventions
in their meta-analysis and concluded that a lifestyle modiﬁcation
intervention resolved MetS approximately 2.0 times more often
compared with the control group (95% CI 1.5–2.7). These lifestyle
interventions led to signiﬁcant reductions in systolic blood pres-
sure, triglyceride levels, waist circumference and fasting blood
glucose levels. Edwardson et al. (2012) showed that more time
spent in sedentary behaviour increased the odds of MetS by
73% (OR 1.73, 95% CI 1.55–1.94; P < 0.0001). Blüher et al. (2014)
studied obese and overweight children, providing them with a one-
year lifestyle intervention which contained regular exercise, diet
counselling, healthy meal preparation, psychological counselling,
education about the medical background of obesity and educa-
tion of parents. After the intervention they measured signiﬁcant
improvements in anthropometric parameters and body composi-
tion as well as metabolic risk markers and glycaemic control. For
example, the standard deviation score, a normalized score for com-
parison between children of different age and sex, for percentage
body fat was 1.79 at baseline and decreased by −0.14 (95% CI −0.18,
−0.02; P = 0.01). HbA1c levels also decreased from 5.5% ± 0.08% at
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o signiﬁcant differences in insulin levels were found, but a sig-
iﬁcant decrease in FFA (0.72 ± 0.03 vs. 0.60 ± 0.04; p = 0.03) was
bserved (Blüher et al., 2014). Dalleck et al. (2013) reported a study
f 142 men  and 190 women (age 28–88) who participated in a 14-
eek exercise intervention. All components of MetS, except total
holesterol, improved signiﬁcantly between baseline and 14 weeks,
ith an absolute elevated energy expenditure of +226.4% kcal/week
n men  and +191.3% kcal/week in women (Dalleck et al., 2013). Lee
t al. (2014) found that adults who practice leisure-time running
ave a 30% and 45% lower adjusted risk of all-cause and cardiovas-
ular mortality respectively, even with 5–10 min  per day at a speed
f approximately 10 km/h. These data support a healthy lifestyle
s an important part of tackling the MetS, and although (random-
zed controlled) trials are lacking, this is also true for CTIMetS. The
besity-driven background of both entities also plead for this.
.2. Cancer survivor population
Previously, the follow-up of long-term adult and childhood
ancer survivors focused on early relapse detection and prolon-
ation of cancer-free survival. Currently, follow-up also consists
f counselling patients to maintain a healthy long-term survivor-
hip. Oncologists and physicians involved in survivor care should
aise awareness among their patients of the potential effects of can-
er treatment like cardiometabolic late effects and weight gain.
t is assumed that the same strategies can be applied to treat
nd prevent MetS in the general population and CTIMetS in can-
er survivors. However, it is controversial whether the same risk
ssessment can be performed in cancer survivors compared to the
on-cancer population. Accelerated ageing has been described in
esticular cancer survivors, including accelerated atherosclerosis,
evelopment of cardiovascular events at younger attained age, and
remature hormonal ageing (Sprauten et al., 2014). Therefore, one
ay  argue that 10–15 years should be added to age in order to
eceive a more accurate assessment of cardiovascular risk in these
ancer patients, similar to what is advocated in patients with dia-
etes mellitus (Booth et al., 2006) and rheumatoid arthritis (Peters
t al., 2010). Treatment of MetS and CTIMetS consists of lifestyle
nterventions with or without drug therapy. Adequate phar-
acological treatment against CTIMetS with oral anti-diabetics,
tatins and angiotensin converting enzyme inhibitors is important
Grundy et al., 2005) to improve the long-term outcome of cancer
urvivors. Currently, estimating cardiovascular risk and the deci-
ion to initiate drug treatment to prevent cardiovascular disease is
argely based on age. Furthermore, only 10-year risk is predicted,
hereas life time risk assessments for this age group are needed
Berry et al., 2012). Standard guidelines are insufﬁcient in the
ounger cancer survivor population, although these are the patients
hat would probably beneﬁt most (Rugbjerg Kathrine, 2014).
Regarding treatment with lifestyle interventions, Bao et al. eval-
ated exercise in a population-based prospective cohort study in
696 breast cancer survivors. At baseline, the prevalence of MetS
as 55.18%. They found that exercise participation of ≥3.5 h/week
30 min/day) between 6 and 60 months post-diagnosis was
nversely associated with the prevalence of MetS with an adjusted
R of 0.69 (95% CI 0.48–0.98). The most reported type of exercise
as walking (45.40%). Exercising <3.5 h/week did not seem to have
ffect (OR 0.98; 95% CI 0.69–1.40) (Bao et al., 2013).
These results are in accordance with a small exercise inter-
ention study performed by Thomas et al. Breast cancer survivors
ere randomized into a 6 months aerobic exercise intervention
n = 35) or usual care (n = 30). The prevalence of MetS at baseline
as 55.4%. In the intervention group, adhering to the exercise
ntervention resulted in a signiﬁcant (P = 0.009) decrease of the
etS from baseline to 6 months in comparison to non-adherers.
he authors designed a standardised Z-score to allow compari-logy/Hematology 108 (2016) 128–136 133
son of MetS instead of separate components. Z-scores of the MetS
in the exercise and the usual care group were −0.76 ± 0.36 and
0.80 ± 0.42 respectively (Thomas Gwendolyn, 2013). Furthermore,
Ligibel et al. showed that fasting insulin concentrations of breast
cancer patients who attended a 16-week exercise intervention
decreased by an average of 2.86 microU/ml (P = 0.03) in comparison
to a decrease in the usual care group of 0.27 microU/ml (P = 0.65)
(Ligibel et al., 2008). Jones et al. (2014) reported the adjusted rate
ratio for cardiovascular events in survivors of childhood Hodgkin
lymphoma according to physical activity. They found that the rate
of events for patients with zero metabolic equivalent task hours per
week (MET hours/week) was  0.87 for 3–6 MET  hours/week (95% CI
0.56–1.34), 0.45 for 9–12 MET  hours/week (95% CI 0.26–0.80) and
0.47 for 15–21 MET  hours/week (95% CI 0.23–0.95). This shows that
the protective mechanism of physical activity is to a certain extent
dose dependent (Jones et al., 2014).
Besides the fact that cardiorespiratory ﬁtness (CRF) is inversely
related to risk of death, cancer incidence (Lakoski et al., 2015)
and cancer mortality (Schmid and Leitzmann, 2014), it may  also
play a role in the development of MetS. Ekblom et al. (2015)
found that decreased cardiorespiratory ﬁtness is strongly associ-
ated with the prevalence of MetS (OR 0.24, 95%CI 0.12–0.48) and
that increased moderate-to-vigorous activity is associated with
decreased prevalence of MetS (OR: 0.33, 95% CI 0.18–0.61). In a
study with overweight postmenopausal African-American women,
Adams-Campbell et al. (2016) found that lower CRF, deﬁned as
VO2 peak < 22 ml/min/kg, was  associated with higher prevalence
of MetS, abdominal obesity, elevated triglyceride levels and low
HDL-C. Lakka et al. (2003) even suggests that poor CRF is a feature of
MetS. Probably the association between CRF and MetS also exists in
cancer survivors. BMI, body fat percentage and waist circumference
are all inversely associated with CRF in breast cancer survivors. This
association suggests that when one’s BMI, body fat percentage and
waist circumference increases, CRF declines (Orozco et al., 2016).
This relation was  also found in a study with endometrial cancer
survivors. At baseline, obese survivors had poorer CRF (p = 0.002)
and also higher systolic blood pressure (p = 0.018) compared to
non-obese survivors.
Although lifestyle interventions are not a routine part of can-
cer care (Ligibel et al., 2015), these studies support the hypothesis
of exercising as a good and easy accessible intervention against
CTIMetS. Results on the lasting effect of lifestyle interventions
in cancer survivors are still scarce, but the available short-term
evidence is promising. In particular, self-efﬁcacy, education and
tailored interventions seem to have a long-term effect (Demark-
Wahnefried et al., 2007). Nevertheless, it is clear that more and
long-term data on this subject are needed (Ligibel et al., 2015).
4.2.1. Timing
Timing of lifestyle intervention is a relevant and interesting
issue. Lifestyle interventions are most frequently started after com-
pletion of cancer treatment. Mounting evidence on the negative
impact of overweight on the outcome of cancer treatment (Ewertz
et al., 2011; Jiralerspong et al., 2013) has made the issue of tim-
ing lifestyle interventions more urgent. In 2010, the roundtable on
exercise guidelines for cancer survivors from the American College
of Sports Medicine (ACSM) concluded that exercise training both
after and during cancer treatment is safe and results in improve-
ments in physical functioning, quality of life and cancer-related
fatigue in several cancer groups (Schmitz et al., 2010; Courneya
et al., 2013). Nevertheless, it is still unknown if there is a difference
between exercising during or after cancer treatment and to what
extent.
For the prevention of CTIMetS and cardiovascular disease that is
induced by cancer treatment, earlier initiation of a tailored lifestyle
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osition and weight gain, the potential driving force of CTIMetS,
ay  be alleviated or prevented if patients start changing lifestyle
abits early and during treatment. Resistance training may  prevent
xcessive loss of lean body mass, and aerobic training may  increase
hysical functioning and CRF and prevent increase of body fat mass.
lso, bone health can be maintained and bone density loss can be
revented (Winters-Stone et al., 2013). If patients succeed in main-
aining a healthy weight and body composition, the development
f insulin resistance, hyperinsulinaemia and dyslipidaemia may  be
revented. If weight is not maintained, exercise is still an effective
ay to combat the other components of MetS. Another advantage
f initiating an exercise intervention during cancer treatment is
hat patients become acquainted with this lifestyle change and start
ncorporating it into their own lives. Patients who are already exer-
ising can struggle with the intensity and frequency of exercise
uring treatment. A professional intervention can provide support.
Effective lifestyle interventions initiated early during intensive
ancer treatment make optimal use of the “teachable moment”
Demark-Wahnefried et al., 2005), when thoughts about conse-
uences of lifestyle and attempts to inﬂuence outcome of disease
re very common. This contemplation phase appears to be an
ppropriate moment to encourage patients to change unhealthy
ehaviour and provide the tools to do that. Education about lifestyle
nd emphasizing the positive effects of lifestyle change for long-
erm cancer survivorship is helpful at this time.
. Conclusion
Numbers of cancer survivors are increasing as a result of earlier
etection and more effective and intensive treatment strategies.
his has resulted in better overall survival but also in more can-
er treatment related morbidity, like cancer treatment-induced
etabolic syndrome (CTIMetS). CTIMetS differs from non-CTIMetS
n aetiology. However, intervention or prevention strategies, i.e.
ifestyle interventions, can be similar, because they often share an
besity driven background. But this is not the case in all cancer
atients or treatment types. The complexity of MetS is that many
actors play a role, including cardiorespiratory ﬁtness. However,
hen obesity is prevented or treated, the major catalysing compo-
ent is probably been dealt with. Lifestyle interventions, whether
r not provided in a supervised schedule, may  play a key role.
ifestyle interventions are a safe and excellent method for pre-
ention or treatment of CTIMetS, probably even during curative
ystemic treatment. Based on mounting evidence we feel that it is
ustiﬁed to implement lifestyle interventions with the goal to opti-
ize energy balance as a part of standard cancer treatment. The
onger this is postponed, the longer we withhold these patients a
ood opportunity for healthy survivorship. However, we still need
onger follow-up and more data about accurate timing of these
ifestyle interventions. Ultimately, these interventions should also
mprove outcome, including late morbidity and overall mortality.
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